Drug intelligence / Profile preview

DNS-7801

Development stage: Discontinued
Lead developer: Dart NeuroScience
Modality: Small Molecules
Administration: Oral

Overview

DNS-7801 is an orally administered investigational compound developed by Dart NeuroScience for the treatment of Parkinson's disease. It reached Phase II clinical trials as an adjunctive therapy for patients with Parkinson's disease experiencing motor fluctuations, but development was discontinued before completion of Phase II. The precise mechanism of action remains undefined, and it is classified as a new molecular entity within the antiparkinsonian drug class[1][2][3].

Other names: DNS 7801DNS7801DNS-7801

Targets

PDE2 (Phosphodiesterase 2)

Beyond the preview

Go deeper on DNS-7801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNS-7801.

Explore the full profile